Most Popular Angioplasty Web Site
Terumo Interventional Systems Announces Launch of Glidewire Advantage™ Peripheral Guidewire
Wire Provides Value-Added Benefit to Industry Leading Wire Technology

Glidewire Advantage™ Peripheral Guidewire
Glidewire Advantage™
Peripheral Guidewire

September 13, 2009 -- Somerset, New Jersey -- Terumo Interventional Systems has announced the launch of its Glidewire Advantage™ Peripheral Guidewire, a single wire that enables the operator to both cross the lesion and deliver interventional devices such as balloons and stents. The Glidewire Advantage is based upon Terumo’s “gold-standard” Glidewire® technology.

The Glidewire Advantage Peripheral Guidewire combines Terumo’s well-established Glidewire construction on the distal 25 cm with a unique spiral PTFE coating on the proximal end. The result is a guidewire that easily navigates and crosses the lesion, while also providing the operator with excellent tactile feel and support for secure device placement. These two wire sections are seamlessly fused together using Terumo’s proprietary DuoCore™ Technology.

"On selected cases, this may be the only wire we use,” said Vikram S. Kashyap, M.D., Associate Professor of Surgery, Department of Vascular Surgery, Cleveland Clinic Lerner College of Medicine. “Thus, access, sheath placement and intervention can be performed using this and negating two or three other wire choices.”

Terumo’s Glidewire product line, manufactured directly by Terumo for more than 20 years, has long been viewed as the “gold standard” in hydrophilic guidewires. The Glidewire Advantage is Terumo’s response to physicians’ desire to shorten procedure time, improve efficiencies and deliver better patient outcomes.

“ The Glidewire Advantage builds on our industry leading Glidewire technology by providing the Endovascular Specialists with a wire that delivers Glidewire performance with the additional benefit of proximal control and support; this is one wire capable of performing two jobs,” said Susan Anderson, Marketing Manager, Lesion Access. “The one-wire approach has the potential to shorten procedure and fluoroscopy times, as well as reduce the risk of complications that could be associated with multiple wire exchanges.”

For more information, customers can contact Terumo Interventional Systems by calling its Inside Sales Customer Care Team at 800.862.4143 or by visiting

Terumo Interventional Systems
Terumo Interventional Systems (TIS), a strategic business unit of Terumo Medical Corporation, directly markets a full line of guidewires, catheters, introducer sheaths, guiding sheaths and embolization products for use in a multitude of different interventional procedures.

Interventional Radiologists, Interventional Neuroradiologists, Interventional Cardiologists, and Vascular Surgeons are among the medical professionals that depend upon TIS products to access and cross difficult-to-reach lesions, thereby allowing therapeutic intervention in previously unreachable vascular beds.

Terumo Medical Corporation
Founded in 1972 as a Terumo Corporation subsidiary, Terumo Medical Corporation (TMC) develops, manufactures, and markets high-quality medical devices used in a broad range of applications in numerous healthcare markets. TMC manufactures a broad portfolio of needles and syringes, entry-site management products, and a line of sterile connection devices used in hospitals and blood banks worldwide.

Terumo Corporation
Tokyo-based Terumo Corporation is one of the world’s leading medical device manufacturers with $3.0 billion in sales and operations in more than 160 nations. Founded in 1921, the company develops, manufactures, and distributes world-class medical devices including products for use in cardiothoracic surgery, interventional procedures, and transfusion medicine; the company also manufactures a broad array of syringe and hypodermic needle products for hospital and physician office use. Terumo contributes to society by providing valued products and services to the healthcare market and by responding to the needs of healthcare providers and the people they serve. Terumo Corporation’s shares are listed on the first section of the Tokyo Stock Exchange (No. 4543, Reuters symbol <4543.T>, or Bloomberg 4543: JP) and is a component of the Nikkei 225, Japan’s leading stock index.

Source: Terumo Interventional Systems